Controversies Surrounding the Potential Use of Histone Deacetylase Inhibitors for the Treatment of Asthma

Figure 2

The putative SIRT1 activator, resveratrol, has been investigated as a potential therapeutic agent in airway disease. Using ovalbumin sensitization and challenge mouse models of allergic asthma, resveratrol has been shown to inhibit airway hyperresponsiveness and to decrease total and OVA-specific IgE. Further, resveratrol inhibits ovalbumin-mediated increases in IgG2a and Th2 cytokines IL-4 and IL-5 and decreases expression of TGFβ1. Eosinophilia and mucus hypersecretion is also attenuated by resveratrol in the mouse models of allergic airways disease.